Language: English
Published by National Academies Press, 2025
ISBN 10: 0309993822 ISBN 13: 9780309993821
Seller: Books From California, Simi Valley, CA, U.S.A.
paperback. Condition: Fine.
Language: English
Published by National Academies Press, 2025
ISBN 10: 0309993822 ISBN 13: 9780309993821
Seller: Books From California, Simi Valley, CA, U.S.A.
paperback. Condition: Very Good. Cover and edges may have some wear.
Language: English
Published by National Academies Press, 2025
ISBN 10: 0309993822 ISBN 13: 9780309993821
Seller: GreatBookPrices, Columbia, MD, U.S.A.
Condition: New.
Language: English
Published by National Academies Press, 2025
ISBN 10: 0309993822 ISBN 13: 9780309993821
Seller: PBShop.store US, Wood Dale, IL, U.S.A.
PAP. Condition: New. New Book. Shipped from UK. Established seller since 2000.
Language: English
Published by National Academies Press, 2025
ISBN 10: 0309993822 ISBN 13: 9780309993821
Seller: GreatBookPrices, Columbia, MD, U.S.A.
Condition: As New. Unread book in perfect condition.
Language: English
Published by National Academies Press, 2025
ISBN 10: 0309993822 ISBN 13: 9780309993821
Seller: PBShop.store UK, Fairford, GLOS, United Kingdom
PAP. Condition: New. New Book. Shipped from UK. Established seller since 2000.
Language: English
Published by National Academies Press, Washington, 2025
ISBN 10: 0309993822 ISBN 13: 9780309993821
Seller: Grand Eagle Retail, Bensenville, IL, U.S.A.
Paperback. Condition: new. Paperback. The United States is a global leader in biomedical research, generating therapeutic breakthroughs that advance the health of the nation and the world. The public and private sectors contribute to this advancement by funding biomedical research and development. The current level of investment in pharmaceutical development in the United States, while substantial, does not always yield desired health outcomes or meet the needs of patients. Public and private funders face a myriad of challenges that affect their funding decisions and hinder the ability of the drug development system to prioritize disease burden and unmet need - often leaving critical gaps in available treatment options.To better understand these gaps, Gates Ventures and the Peterson Center on Healthcare asked the National Academies to examine current challenges and offer strategies and recommendations for improvement. The resulting report emphasizes that current research prioritization does not systematically account for disease burden and unmet needs, and describes how a robust, timely, accessible data system is needed. It also explores the ways in which implementing recommended policy changes could deliver better health outcomes. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.
Language: English
Published by National Academies Press, 2025
ISBN 10: 0309993822 ISBN 13: 9780309993821
Seller: Chiron Media, Wallingford, United Kingdom
paperback. Condition: New.
Language: English
Published by National Academies Press, 2025
ISBN 10: 0309993822 ISBN 13: 9780309993821
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Condition: New.
Language: English
Published by National Academies Press, 2025
ISBN 10: 0309993822 ISBN 13: 9780309993821
Seller: Revaluation Books, Exeter, United Kingdom
Paperback. Condition: Brand New. 244 pages. 6.10x0.60x9.10 inches. In Stock.
Language: English
Published by National Academies Press, 2025
ISBN 10: 0309993822 ISBN 13: 9780309993821
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Condition: As New. Unread book in perfect condition.
Language: English
Published by National Academies Press, 2025
ISBN 10: 0309993822 ISBN 13: 9780309993821
Seller: THE SAINT BOOKSTORE, Southport, United Kingdom
Paperback / softback. Condition: New. New copy - Usually dispatched within 3 working days.
Language: English
Published by National Academies Press, 2025
ISBN 10: 0309993822 ISBN 13: 9780309993821
Seller: Kennys Bookshop and Art Galleries Ltd., Galway, GY, Ireland
Condition: New. 2025. paperback. . . . . .
Language: English
Published by National Academies Press, 2025
ISBN 10: 0309993822 ISBN 13: 9780309993821
Seller: Kennys Bookstore, Olney, MD, U.S.A.
Condition: New. 2025. paperback. . . . . . Books ship from the US and Ireland.
Language: English
Published by National Academies Press, 2025
ISBN 10: 0309993822 ISBN 13: 9780309993821
Seller: Revaluation Books, Exeter, United Kingdom
Paperback. Condition: Brand New. 244 pages. 6.10x0.60x9.10 inches. In Stock.
Language: English
Published by National Academies Press, Washington, 2025
ISBN 10: 0309993822 ISBN 13: 9780309993821
Seller: CitiRetail, Stevenage, United Kingdom
Paperback. Condition: new. Paperback. The United States is a global leader in biomedical research, generating therapeutic breakthroughs that advance the health of the nation and the world. The public and private sectors contribute to this advancement by funding biomedical research and development. The current level of investment in pharmaceutical development in the United States, while substantial, does not always yield desired health outcomes or meet the needs of patients. Public and private funders face a myriad of challenges that affect their funding decisions and hinder the ability of the drug development system to prioritize disease burden and unmet need - often leaving critical gaps in available treatment options.To better understand these gaps, Gates Ventures and the Peterson Center on Healthcare asked the National Academies to examine current challenges and offer strategies and recommendations for improvement. The resulting report emphasizes that current research prioritization does not systematically account for disease burden and unmet needs, and describes how a robust, timely, accessible data system is needed. It also explores the ways in which implementing recommended policy changes could deliver better health outcomes. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.
Language: English
Published by National Academies Press, Washington, 2025
ISBN 10: 0309993822 ISBN 13: 9780309993821
Seller: AussieBookSeller, Truganina, VIC, Australia
Paperback. Condition: new. Paperback. The United States is a global leader in biomedical research, generating therapeutic breakthroughs that advance the health of the nation and the world. The public and private sectors contribute to this advancement by funding biomedical research and development. The current level of investment in pharmaceutical development in the United States, while substantial, does not always yield desired health outcomes or meet the needs of patients. Public and private funders face a myriad of challenges that affect their funding decisions and hinder the ability of the drug development system to prioritize disease burden and unmet need - often leaving critical gaps in available treatment options.To better understand these gaps, Gates Ventures and the Peterson Center on Healthcare asked the National Academies to examine current challenges and offer strategies and recommendations for improvement. The resulting report emphasizes that current research prioritization does not systematically account for disease burden and unmet needs, and describes how a robust, timely, accessible data system is needed. It also explores the ways in which implementing recommended policy changes could deliver better health outcomes. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.
Language: English
Published by National Academies Press Sep 2025, 2025
ISBN 10: 0309993822 ISBN 13: 9780309993821
Seller: AHA-BUCH GmbH, Einbeck, Germany
Taschenbuch. Condition: Neu. Neuware - The United States is a global leader in biomedical research, generating therapeutic breakthroughs that advance the health of the nation and the world. The public and private sectors contribute to this advancement by funding biomedical research and development. The current level of investment in pharmaceutical development in the United States, while substantial, does not always yield desired health outcomes or meet the needs of patients. Public and private funders face a myriad of challenges that affect their funding decisions and hinder the ability of the drug development system to prioritize disease burden and unmet need - often leaving critical gaps in available treatment options.